Transcranial Magnetic Stimulation in Misophonia

Not Applicable

Not yet recruiting

• Conditions: Misophonia

• Registration Number: NCT06960083
• Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary

The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-04-14
• Study First Submitted QC: 2025-04-28
• Study First Posted: 2025-05-07
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-12
• Last Update Posted: 2025-06-13
• Study Start: 2025-06-30
• Primary Completion: 2026-06-30
• Study Completion: 2026-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear.
• Must be between the ages of 18 - 55.
• Must be fluent in English since the study's instructions, surveys, and tasks will be in English.

Exclusion Criteria

• Axis I Psychiatric condition, past or present, as defined in DSM-V.
• Disability or medical condition that prohibits completion of study. Participants must be able to complete all study procedures to ensure optimal conditions for data analysis.
• Central Nervous System (CNS) disease, such as history of brain abnormalities (e.g., neoplasms, subarachnoid cysts), cerebrovascular disease, infectious disease (e.g., abscess), or other neurological diseases, history of head trauma (defined as loss of consciousness>3 min), or history of seizures without a resolved etiology. CNS disease and drugs that act in the peripheral or central nervous system are likely to have effects on patterns of neural activity.
• Recent or regular use of psychotropic medication (e.g., amitriptyline for migraines).
• Recent use of drugs of abuse.
• Presence of any mental implants in the head.
• Pregnant or lactating.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Unpleasantness Rating Scale	after each session, 72 hours apart (each session is 2 hours)	Participants will be presented with a slider with extremes labelled as extremely unpleasant and extremely pleasant. Ratings will be provided for audio clips and visual cues. Full scale from 0-100, higher score indicates more unpleasantness

Secondary Outcome Measures

Name	Time	Method
Heart Rate	after each session, 72 hours apart (each session is 2 hours)	The heart rate (number of beats per minute) will be measured using a wristwatch worn by the participant.
Skin Conductance Response	after each session, 72 hours apart (each session is 2 hours)	Skin conductance, a measure capturing the amount of sweat, will be measured using a wristwatch worn by the participant.
EEG P1-N1-P2 Complex Peak Amplitude	after each session, 72 hours apart (each session is 2 hours)	Amplitude (microvolts) of P1, N1, and P2 peaks measured in the parietal region
EEG P1-N1-P2 Complex Peak Latency	after each session, 72 hours apart (each session is 2 hours)	Latency (milliseconds) of P1, N1, and P2 peaks measured in the parietal region
EEG Frequency Band Amplitude	after each session, 72 hours apart (each session is 2 hours)	Amplitude (decibel) in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region
EEG Frequency Band Inter-Trial Coherence	after each session, 72 hours apart (each session is 2 hours)	Coherence (unitless) across trials in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region

Trial Locations

Locations (1)

Mount Sinai West; 🇺🇸 New York, New York, United States